Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Cyclophosphamide 172Rituximab 161Specimen Handling 115Biopsy 92Magnetic Resonance Spectroscopy 90Vincristine 88Doxorubicin 82Prednisone 80fludarabine 71venetoclax 70obinutuzumab 63Lenalidomide 56ibrutinib 55Dexamethasone 55Cytarabine 49Methotrexate 47acalabrutinib 43Etoposide 43CT-P10 41blinatumomab 38fludarabine phosphate 35Bendamustine Hydrochloride 35Gemcitabine 33prednylidene 32zanubrutinib 31deltacortene 31pembrolizumab 30Calcium Dobesilate 30glofitamab 29Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ibritumomab tiuxetan × Lymphoid × 90 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡